PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29070105-1 2017 OBJECTIVE: To investigate the mechanism of reversing drug resistance of K562/D cells to daunorubicin by Embelin and its relationship with P-gp and MDR1 mRNA. Daunorubicin 88-100 phosphoglycolate phosphatase Homo sapiens 138-142 28277825-7 2017 RESULTS: In vitro results showed that WGA modified daunorubicin anti-resistant liposomes exhibited suitable physicochemical properties, significantly increased intracellular uptake in both MCF-7 cells and MCF-7/ADR cells, and circumvented the multidrug resistance via inhibiting P-gp. Daunorubicin 51-63 phosphoglycolate phosphatase Homo sapiens 279-283 26027258-6 2015 However, the results of inhibitor analysis of input of Pgp-dependent mechanisms of accumulation of rodamin-123 by leukocytes differ the data received under application of daunorubicin that reflects differences of their intracellular binding sites. Daunorubicin 171-183 phosphoglycolate phosphatase Homo sapiens 55-58 17524504-7 2007 Furthermore, the intracellular accumulation of daunorubicin, a substrate for P-gp, increased significantly with an increased intracellular localisation of P-gp-EGFP. Daunorubicin 47-59 phosphoglycolate phosphatase Homo sapiens 77-81 21133625-8 2010 The association of CC genotype with clinical variables in ALL indicated that the CC genotype with high expression might be eliminating antileukemic drugs (anthracyclines, Daunorubicin, Vincristeine, Mitoxanthrone) which are P-gp substrates, leading to lower intra cellular drug concentrations and a poor prognosis. Daunorubicin 171-183 phosphoglycolate phosphatase Homo sapiens 224-228 19840446-0 2009 [Effect of tetrandrine combined with daunorubicin on expressions of P21 and P-gp in K562/A02 cells]. Daunorubicin 37-49 phosphoglycolate phosphatase Homo sapiens 76-80 17524504-7 2007 Furthermore, the intracellular accumulation of daunorubicin, a substrate for P-gp, increased significantly with an increased intracellular localisation of P-gp-EGFP. Daunorubicin 47-59 phosphoglycolate phosphatase Homo sapiens 155-164 17274671-0 2007 Modifying the sugar moieties of daunorubicin overcomes P-gp-mediated multidrug resistance. Daunorubicin 32-44 phosphoglycolate phosphatase Homo sapiens 55-59 16955376-2 2006 PROCEDURE: Pgp inhibition was measured by daunorubicin transport assays and fluorescence microscopy in resistant A2780/Adr cells treated with WK-X-34 and antisense. Daunorubicin 42-54 phosphoglycolate phosphatase Homo sapiens 11-14 16111844-5 2005 In the presence of NP-9, the apical uptake of daunomycin was increased, suggesting competitive inhibition between NP-9 and daunomycin in the efflux via the P-gp system. Daunorubicin 46-56 phosphoglycolate phosphatase Homo sapiens 156-160 16856922-2 2006 Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that liposomal-encapsulated DNR (Daunoxome-DNX) is more toxic than DNR against ALL cell lines. Daunorubicin 30-42 phosphoglycolate phosphatase Homo sapiens 104-107 16856922-2 2006 Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that liposomal-encapsulated DNR (Daunoxome-DNX) is more toxic than DNR against ALL cell lines. Daunorubicin 165-168 phosphoglycolate phosphatase Homo sapiens 104-107 16111844-5 2005 In the presence of NP-9, the apical uptake of daunomycin was increased, suggesting competitive inhibition between NP-9 and daunomycin in the efflux via the P-gp system. Daunorubicin 123-133 phosphoglycolate phosphatase Homo sapiens 156-160 15375376-5 2004 The reversal of MDR was accompanied by a complete suppression of MDR1/P-gp expression on mRNA and protein level, and by a considerable increased intracellular anthracyline accumulation in the anti-MDR1/P-gp shRNA-treated cells. Daunorubicin 159-171 phosphoglycolate phosphatase Homo sapiens 202-206 12820137-7 2003 In summary, the canalicular excretion of P-gp substrates, such as daunomycin, might be reduced in patients with PCM via a mechanism involving the suppression of the expression of P-gp. Daunorubicin 66-76 phosphoglycolate phosphatase Homo sapiens 41-45 12820137-7 2003 In summary, the canalicular excretion of P-gp substrates, such as daunomycin, might be reduced in patients with PCM via a mechanism involving the suppression of the expression of P-gp. Daunorubicin 66-76 phosphoglycolate phosphatase Homo sapiens 179-183 12647012-0 2003 Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Daunorubicin 105-117 phosphoglycolate phosphatase Homo sapiens 89-93 12647012-1 2003 PURPOSE: To investigate the effects of arsenic trioxide (As(2)O(3)) on human T-lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 (MOLT-4/DNR) cells. Daunorubicin 136-148 phosphoglycolate phosphatase Homo sapiens 120-124 10746169-1 1999 The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments. Daunorubicin 97-109 phosphoglycolate phosphatase Homo sapiens 55-59 10865967-1 2000 The expression of the drug transport protein, P-glycoprotein (Pgp/MDR1) has been found to be of prognostic significance for the achievement of complete remission (CR) or the duration of survival after daunorubicin (DNR)-containing induction therapy in acute myeloid leukemia (AML). Daunorubicin 201-213 phosphoglycolate phosphatase Homo sapiens 62-65 10685076-9 2000 After long-term exposure to daunorubicin and acquisition of drug resistance, expression of P-gp was accompanied by a decrease in the number of Fas sites at the cell surface with a correlated desensitization to Fas-induced apoptosis. Daunorubicin 28-40 phosphoglycolate phosphatase Homo sapiens 91-95 10586216-0 1999 Liposome encapsulated daunorubicin doubles anthracycline toxicity in cell lines showing a non-PGP related multidrug resistance. Daunorubicin 22-34 phosphoglycolate phosphatase Homo sapiens 94-97 10746169-4 1999 [3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp. Daunorubicin 82-94 phosphoglycolate phosphatase Homo sapiens 145-149 10746169-4 1999 [3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp. Daunorubicin 82-94 phosphoglycolate phosphatase Homo sapiens 215-219 10419897-0 1999 Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Daunorubicin 80-92 phosphoglycolate phosphatase Homo sapiens 34-37 10630360-6 1999 There was a strong inverse correlation between P-gp levels and cellular drug accumulation (rho = -0.83, p = 0.04) and cytotoxicity (rho = -0.95, p = 0.01) of daunorubicin. Daunorubicin 158-170 phosphoglycolate phosphatase Homo sapiens 47-51 10630360-7 1999 Also the cytotoxicity of DaunoXome and doxorubicin was related to P-gp levels (rho = -0.96, p = 0.01 and rho = -0.90, p = 0.07, respectively). Daunorubicin 25-34 phosphoglycolate phosphatase Homo sapiens 66-70 7945406-2 1994 We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein. Daunorubicin 31-43 phosphoglycolate phosphatase Homo sapiens 152-155 7945406-2 1994 We have recently reported that daunorubicin (DNR) accumulation was decreased in the multidrug resistance-associated protein overexpressing GLC4/ADR non-Pgp MDR small cell lung cancer cell line due to an enhanced energy-dependent efflux which could be inhibited by the isoflavonoid genistein. Daunorubicin 45-48 phosphoglycolate phosphatase Homo sapiens 152-155 7906263-0 1994 5"-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression. Daunorubicin 35-47 phosphoglycolate phosphatase Homo sapiens 117-121 10444168-0 1999 Liposome-encapsulated daunorubicin for PGP-related multidrug resistance. Daunorubicin 22-34 phosphoglycolate phosphatase Homo sapiens 39-42 10444168-1 1999 The possibility that Daunoxome (DNX), a combination of daunorubicin (DNR) with a liposomal targeting system, escapes PGP was tested. Daunorubicin 21-30 phosphoglycolate phosphatase Homo sapiens 117-120 10444168-1 1999 The possibility that Daunoxome (DNX), a combination of daunorubicin (DNR) with a liposomal targeting system, escapes PGP was tested. Daunorubicin 32-35 phosphoglycolate phosphatase Homo sapiens 117-120 10444168-6 1999 In 15 cases with a low PGP expression intracellular DNR accumulation was faster and higher with free DNR than with DNX. Daunorubicin 115-118 phosphoglycolate phosphatase Homo sapiens 23-26 9150713-2 1997 By the addition of MS-209, the intracellular daunorubicin (DNR) contents which had been found to be low in P-gp-positive AML blasts and in K562/ADM were significantly enhanced to the level of P-gp-negative blasts and that of sensitive K562. Daunorubicin 45-57 phosphoglycolate phosphatase Homo sapiens 107-111 9150713-2 1997 By the addition of MS-209, the intracellular daunorubicin (DNR) contents which had been found to be low in P-gp-positive AML blasts and in K562/ADM were significantly enhanced to the level of P-gp-negative blasts and that of sensitive K562. Daunorubicin 45-57 phosphoglycolate phosphatase Homo sapiens 192-196 7773504-18 1995 This indicates that in resistant cells intracellular DAU at least in part may be inaccessible for P-Gp and that vesicular drug transport appears to contribute to DAU resistance by removing intracellular DAU via exocytosis. Daunorubicin 53-56 phosphoglycolate phosphatase Homo sapiens 98-102